CHB


China Biotech Innovation ETF

Reasons to Consider CHB

High Growth Potential

Forecasts suggest China’s biotech market could grow from nearly $23bn in 2020 to more than $35bn by 2025.1

Structural Tailwinds

Health care expenditures in China have grown at an annualized rate of 20% since 2003.2 We believe biotech companies are well-positioned to benefit from further growth in this sector.

Targeted Exposure

In contrast to other funds that offer global or broader health care sector exposure, CHB specifically targets the biotech industry in China.

1Research and Markets, Oct 2021
2Council on Foreign Relations, May 2021

Key Information As of 05/17/22

Inception Date 09/22/20
Total Expense Ratio 0.65%
Net Assets $2.57 million
NAV $9.52
Fact Sheet

ETF Summary

The Global X China Biotech Innovation ETF (CHB) seeks to invest in companies that are directly involved in China’s biotechnology industry.

ETF Objective

The Global X China Biotech Innovation ETF (CHB) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Solactive China Biotech Innovation Index.

Trading Details As of 05/17/22

Ticker CHB
Bloomberg Index Ticker SOLCHB
CUSIP 37954Y251
ISIN US37954Y2515
Primary Exchange Nasdaq
Shares Outstanding 270,000
Number of Holdings 34
30-Day Median Bid-Ask Spread 1.01%

Distributions As of 05/17/22

30-Day SEC Yield 0.19%
Distribution Frequency Semi-Annually

ETF Prices As of 05/17/22

NAV $9.52 Daily Change -$0.03 -0.34%
Market Price $9.44 Daily Change -$0.08 -0.84%

Performance History

As of recent
(03/31/22)
As of recent
(03/31/22)
Fund NAV Market Price Index
1 Year -27.65% -28.90% -27.15%
Since Inception -15.54% -16.15% -15.00%
1 Year -46.69% -47.28% -46.39%
Since Inception -22.70% -23.14% -22.26%
Year-to-Date -18.79% -19.19% -18.64%
1 Month -3.71% -4.63% -3.62%
3 Months -18.79% -19.19% -18.64%
Since Inception -22.66% -23.53% -21.90%
Year-to-Date -30.55% -30.74% -30.43%
1 Month -14.48% -14.30% -14.49%
3 Months -16.49% -17.79% -16.37%
Since Inception -33.86% -34.46% -33.21%

Cumulative return is the aggregate amount that an investment has gained or lost over time. Annualized return is the average return gained or lost by an investment each year over a given time period.

The performance data quoted represents past performance. Past performance does not guarantee future results. The investment return and principal value of an investment will fluctuate so that an investor's shares, when sold or redeemed, may be worth more or less than their original cost and current performance may be lower or higher than the performance quoted. High short-term performance of the Fund, when observed, is unusual and investors should not expect such performance to be repeated.

Top Holdings As of 05/17/22

Net Assets (%) Ticker Name SEDOL Market Price ($) Shares Held Market Value ($)
8.19 1093 HK CSPC PHARMACEUTI 6191997 1.01 208,000 210,391.41
8.16 000661 C2 CHANGCHUN HIGH-A BD5CDB3 22.45 9,347 209,802.75
7.95 2269 HK WUXI BIOLOGICS CAYMAN INC BL6B9P1 6.92 29,550 204,409.69
7.69 300142 C2 WALVAX BIOTECHNOLOGY CO-A BD5CG36 7.14 27,700 197,679.62
7.59 300122 C2 CHONGQING ZHIF-A BD5CJY8 13.84 14,100 195,099.99
4.50 1548 HK GENSCRIPT BIOTECH CORP BD9Q2J2 2.66 43,550 115,674.70
4.47 603345 C1 ANJOY FOODS GR-A BMXWM11 18.97 6,051 114,812.72
3.77 002030 C2 DAAN GENE CO LTD-A BD5CKW3 2.50 38,780 96,851.51
3.77 ZLAB ZAI LAB LTD-ADR BD9GVY0 35.35 2,738 96,788.30
3.75 300601 C2 SHENZHEN KANGT-A BFY8HT2 8.48 11,371 96,477.74
3.53 603392 C1 BEIJING WANTAI-A BMXTWX4 25.06 3,615 90,599.50
3.43 002007 C2 HUALAN BIOLOGI-A BD5CL19 2.43 36,300 88,235.24
3.35 300676 C2 BGI GENOMICS CO LTD-A BFY8H58 9.73 8,838 85,983.35
3.29 603127 C1 JOINN LABORATO-A BK94819 14.43 5,860 84,543.00
3.13 002252 C2 SHANGHAI RAAS -A BD5CPJ5 0.82 98,000 80,517.88
3.03 600161 C1 BEIJING TIAN-A BP3R9J4 3.10 25,057 77,740.49
2.78 002422 C2 SICHUAN KELUN-A BD5CL08 2.64 27,100 71,459.10
2.77 300725 C2 PHARMABLOCK SC-A BFY8HC5 12.33 5,781 71,254.57
2.35 300482 C2 GUANGZHOU WOND-A BFY8GZ1 6.23 9,700 60,448.33
1.83 1530 HK 3SBIO INC BY9D3L9 0.71 66,500 46,932.70
1.29 000078 C2 SHENZ NEPTUNUS-A BD5CBK8 0.52 63,400 33,096.98
1.28 002038 C2 BEIJING SL -A BD5CJD7 1.52 21,700 32,986.79
1.27 300639 C2 GUANGDONG HYBR-A BMQBTJ2 3.34 9,763 32,563.36
0.87 603387 C1 GETEIN BIOTECH INC-A BFB4S90 2.85 7,800 22,244.90
0.85 300841 C2 CHENGDU KANGHU-A BMXVCN0 18.16 1,200 21,797.31
0.72 9939 HK KINTOR PHARMACEUTICAL LTD BMDWVN6 2.53 7,300 18,450.52
0.64 300255 C2 HEBEI CHANGSHA-A BD5LWT1 0.93 17,700 16,537.52
0.64 000710 C2 BERRY GENOMICS CO LTD-A BFFJRH2 1.98 8,355 16,529.46
0.63 9966 HK ALPHAMAB ONCOLOGY BL6WGG4 0.88 18,400 16,126.88
0.54 688366 C1 SHANGHAI HAOHA-A BLCD7D5 11.12 1,255 13,955.51
0.46 300318 C2 BEIJING BOHUI -A BMQBTF8 0.91 12,900 11,708.40
0.41 6855 HK ASCENTAGE PHARMA BK9PZW2 1.66 6,400 10,631.68
0.41 1873 HK VIVA BIOTECH HOLDINGS BJBL0L5 0.29 37,000 10,605.43
0.34 2126 HK JW CAYMAN THERAP BN4NLR9 0.90 9,600 8,646.39
0.32 CASH 1.00 8,194 8,194.16
Holdings are subject to change.

ETF Characteristics As of 05/17/22

Return on Equity 8.20%
Weighted Avg. Market Cap 8,316 M
2021 2022
Price-to-earnings 55.67 45.46
Price-to-book value 3.84 3.61

Source: AltaVista Research, LLC

ETF Risk Stats As of 05/17/22

Versus Beta
S&P 500 0.41
MSCI EAFE 0.25
MSCI Emg. Mkts 0.73
Standard Deviation 26.10%

Source: AltaVista Research, LLC

ETF Research

View More Related Research

Investing involves risk, including the possible loss of principal. International investments may involve risk of capital loss from unfavorable fluctuation in currency values, from differences in generally accepted accounting principles, or from economic or political instability in other nations. Emerging markets involve heightened risks related to the same factors as well as increased volatility and lower trading volume. Investments in securities in the Biotechnology and Health Care sectors can be affected by government regulations, rapid product obsolescence, intense industry competition and loss or impairment of patents or intellectual property rights. Securities focusing on a single country and narrowly focused investments may be subject to higher volatility. CHB is non-diversified.

Shares of ETFs are bought and sold at market price (not NAV) and are not individually redeemed from the Fund. Brokerage commissions will reduce returns. Beginning October 15, 2020, market price returns are based on the official closing price of an ETF share or, if the official closing price isn’t available, the midpoint between the national best bid and national best offer (“NBBO”) as of the time the ETF calculates current NAV per share. Prior to October 15, 2020, market price returns were based on the midpoint between the Bid and Ask price. NAVs are calculated using prices as of 4:00 PM Eastern Time. The returns shown do not represent the returns you would receive if you traded shares at other times. Indices are unmanaged and do not include the effect of fees, expenses or sales charges. One cannot invest directly in an index.

Since the Fund’s shares typically do not trade in the secondary market until several days after the Fund’s inception, for the period from inception to the first day of secondary market trading in Shares, the NAV of the Fund is used to calculate market returns.

Carefully consider the Fund’s investment objectives, risks, and charges and expenses before investing. This and other information can be found in the Fund’s summary or full prospectuses. Please read the prospectus carefully before investing.

Global X Management Company LLC serves as an advisor to Global X Funds. The Funds are distributed by SEI Investments Distribution Co. (SIDCO), which is not affiliated with Global X Management Company LLC or Mirae Asset Global Investments. Global X Funds are not sponsored, endorsed, issued, sold or promoted by Solactive AG, nor does Solactive AG make any representations regarding the advisability of investing in the Global X Funds. Neither SIDCO, Global X nor Mirae Asset Global Investments are affiliated with Solactive AG.

Back to Top